Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.,Journal of Oncology Pharmacy Practice

当前位置： X-MOL 学术 › J. Oncol. Pharm. Pract. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.
Journal of Oncology Pharmacy Practice ( IF 1.3 ) Pub Date : 2020-05-19 , DOI: 10.1177/1078155220924084
Emre Yekedüz _{1,

2} , Bengü Dursun _{1,

2} , Güle Ç Aydın ₃ , Satı C Yazgan ₄ , Halis H Öztürk ₅ , Alpay Azap ₃ , Güngör Utkan _{1,

2} , Yüksel Ürün _{1,

2}

Affiliation

Outbreak of the new type coronavirus infection, known as coronavirus infection 2019 (COVID-19), has begun in December 2019, in Wuhan, China. As of today, 3 April 2020, 972,640 people affected and 50,325 people died from Severe Acute Respiratory Syndrome-Coronavirus 2. There is not any standard treatment for coronavirus infection 2019; however, there are promising data for hydroxychloroquine and some anti-retroviral drugs. Programmed death-1 (PD-1)/programmed death ligand-1 (PDL-1) pathway is an important target for the cancer immunotherapy. However, there is a robust pre-clinical and clinical data regarding inhibitor effect of this pathway on the acute or chronic viral infections. Thus, blockade of this pathway may lead to an anti-viral effect and decrease viral load. Here, we report the clinical course of coronavirus infection 2019 infection of a patient in whom older aged, having multiple co-morbidities, and taking nivolumab for metastatic malignant melanoma. In contrast to her older age, comorbidities, and cancer diagnosis, she was in a good condition, and there was also no pneumonia finding. We think that this good clinical course of coronavirus infection 2019 infection may be related to blockade of PD-1/PDL-1 pathway with nivolumab. It is impossible to say that blockade of PD-1/PDL-1pathway is a treatment option for COVID-19; however, we want to share our experience.

更新日期：2020-05-19

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>